Oxler Private Wealth LLC Sells 58 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Oxler Private Wealth LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,939 shares of the medical research company’s stock after selling 58 shares during the quarter. Thermo Fisher Scientific comprises 1.7% of Oxler Private Wealth LLC’s portfolio, making the stock its 16th biggest holding. Oxler Private Wealth LLC’s holdings in Thermo Fisher Scientific were worth $5,170,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Quarry LP increased its stake in shares of Thermo Fisher Scientific by 86.2% in the second quarter. Quarry LP now owns 121 shares of the medical research company’s stock worth $67,000 after purchasing an additional 56 shares during the period. Mattson Financial Services LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter worth $1,078,000. AMF Tjanstepension AB bought a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth about $42,409,000. Czech National Bank lifted its stake in shares of Thermo Fisher Scientific by 7.0% in the third quarter. Czech National Bank now owns 77,816 shares of the medical research company’s stock valued at $48,135,000 after buying an additional 5,076 shares during the period. Finally, Farmers Trust Co. increased its stake in Thermo Fisher Scientific by 70.9% during the third quarter. Farmers Trust Co. now owns 622 shares of the medical research company’s stock valued at $385,000 after acquiring an additional 258 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Robert W. Baird reduced their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 price objective for the company. Scotiabank started coverage on shares of Thermo Fisher Scientific in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $605.00 price target for the company. Morgan Stanley lifted their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a report on Friday. Finally, TD Cowen raised their target price on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $655.64.

Thermo Fisher Scientific Trading Down 1.4 %

TMO opened at $598.40 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company has a market cap of $228.89 billion, a price-to-earnings ratio of 37.52, a price-to-earnings-growth ratio of 3.89 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The firm has a 50 day simple moving average of $539.66 and a 200 day simple moving average of $570.59.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a $0.39 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock repurchase program on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 9,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, November 8th. The shares were sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the transaction, the chief executive officer now directly owns 14,608 shares of the company’s stock, valued at $8,076,178.88. This trade represents a 38.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 29,000 shares of company stock valued at $15,859,540 in the last 90 days. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.